Journal List > Tuberc Respir Dis > v.65(6) > 1001315

TOOLS
Um, Kim, Kwon, Han, and Shim: Prognostic Value of p53 Overexpression in Patients with Pathologic Stage I Non-small Cell Lung Cancer
Original Article
Tuberculosis and Respiratory Diseases

Tuberculosis and Respiratory Diseases 2008; 65(6): 487-494.

Published online: 31 December 2008

DOI: https://doi.org/10.4046/trd.2008.65.6.487

Prognostic Value of p53 Overexpression in Patients with Pathologic Stage I Non-small Cell Lung Cancer

Sang-Won Um, M.D.1, Hojoong Kim, M.D.1, O Jung Kwon, M.D.1, Joungho Han, M.D.2, Young Mog Shim, M.D.3

1Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

2Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

3Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Address for correspondence: Hojoong Kim, M.D. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50, Irwon-dong, Gangnam-gu, Seoul 135-710, Korea. Phone: 82-2-3410-3429, Fax: 82-2-3410-6956, hjk3425@skku.edu

Received 20 September 2008       Accepted 8 October 2008

Copyright © 2008 The Korean Academy of Tuberculosis and Respiratory Diseases

Abstract

Background

Chromosome 17p allele losses and mutations of p53 gene are the most common genetic abnormalities in lung cancer. The purposes of this study were to evaluate the factors associated with p53 protein overexpression and to evaluate its prognostic value in patients with pathologic stage I non-small cell lung cancer (NSCLC).

Methods

This is a retrospective review for the patients who underwent surgical resection at Samsung Medical Center between Jan 2003 and Jun 2004. Immunohistochemical staining for p53 protein was performed on tumor tissues from patients with lung cancer. The p53 overexpression was evaluated in relation to age, sex, smoking history, histology and pathologic stage by univariate and multivariate analyses. The disease-free survival (DFS), disease-specific survival (DSS) and overall survival (OS) were analyzed using the Kaplan-Meier methods and the differences in DFS, DSS and OS were assessed by using the log-rank tests.

Results

A total of 125 patients were included in the analysis and a median frequency of p53 expression in tumor tissue was 10%. The p53 overexpression (≥10%) was more common in squamous cell carcinoma (66%) than in adenocarcinoma (38%, p=0.002). The p53 overexpression was more common in pathologic stage IB (59%) than in IA (38%, p=0.002). Patients with p53-overexpressing tumor (27 years) smoked more years compared with those without it (20 years, p=0.032). Smoking history ≥25 pack-years was more common in patients with p53 overexpression (58%) than in those without it (38%, p=0.024). In the multivariate analysis, only histology was significantly associated with p53 overexpression. However, there were no significant differences of DFS, DSS and OS in relation to p53 status.

Conclusion

The p53 overexpression was associated with histology, pathologic stage and smoking history in patients with pathologic stage I NSCLC. However, the p53 overexpression was not associated with patient's survival.

Keywords: p53, Smoking, Non-small cell lung cancer, Survival

Figures and Tables

Figure 1
Disease-free survival (DFS), disease-specific survival (DSS) and overall survival (OS) of patients with lung cancer in relation to p53 overexpression (≥10%).
trd-65-487-g001
Table 1
Clinical characteristics of 125 study patients
trd-65-487-i001
Table 2
Characteristics of patients and biologic features of tumor: comparison according to p53 status
trd-65-487-i002

Data are presented as mean±standard deviation or number (%).

*Six cases are missing due to unavailability for the histologic grade of differentiation, †pack per day.

References

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006. 56:106–130.
2. Yokota J, Sugimura T. Multiple steps in carcinogenesis involving alterations of multiple tumor suppressor genes. FASEB J. 1993. 7:920–925.
3. Shiseki M, Kohno T, Adachi J, Okazaki T, Otsuka T, Mizoguchi H, et al. Comparative allelotype of early and advanced stage non-small cell lung carcinomas. Genes Chromosomes Cancer. 1996. 17:71–77.
4. Kishimoto Y, Murakami Y, Shiraishi M, Hayashi K, Sekiya T. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res. 1992. 52:4799–4804.
5. Sun Y. p53 and its downstream proteins as molecular targets of cancer. Mol Carcinog. 2006. 45:409–415.
6. Ferreira CG, Tolis C, Giaccone G. p53 and chemosensitivity. Ann Oncol. 1999. 10:1011–1021.
7. Tammemagi MC, McLaughlin JR, Mullen JB, Bull SB, Johnston MR, Tsao MS, et al. A study of smoking, p53 tumor suppressor gene alterations and non-small cell lung cancer. Ann Epidemiol. 2000. 10:176–185.
8. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry?--Revisited! J Pathol. 1994. 172:1–4.
9. Tammemagi MC, McLaughlin JR, Bull SB. Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. Cancer Epidemiol Biomarkers Prev. 1999. 8:625–634.
10. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res. 2000. 6:4055–4063.
11. Tanaka F, Takata T, Yamada T, Yanagihara K, Otake Y, Miyahara R, et al. Apoptotic tumor-cell death in response to cell proliferation is influenced by p53 status in resected non-small cell lung cancer. Lung Cancer. 2002. 36:27–32.
12. Lung ML, Wong MP, Skaanild MT, Fok CL, Lam WK, Yew WW. p53 mutations in non-small cell lung carcinomas in Hong Kong. Chest. 1996. 109:718–726.
13. Haque AK, Au W, Cajas-Salazar N, Khan S, Ginzel AW, Jones DV, et al. CYP2E1 polymorphism, cigarette smoking, p53 expression, and survival in non-small cell lung cancer: a long term follow-up study. Appl Immunohistochem Mol Morphol. 2004. 12:315–322.
14. Esposito V, Baldi A, De Luca A, Micheli P, Mazzarella G, Baldi F, et al. Prognostic value of p53 in non-small cell lung cancer: relationship with proliferating cell nuclear antigen and cigarette smoking. Hum Pathol. 1997. 28:233–237.
15. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997. 111:1710–1717.
16. Westra WH, Offerhaus GJ, Goodman SN, Slebos RJ, Polak M, Baas IO, et al. Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol. 1993. 17:213–220.
17. Gosney JR, Butt SA, Gosney MA, Field JK. Exposure to cigarette smoke and expression of the protein encoded by the p53 gene in bronchial carcinoma. Ann N Y Acad Sci. 1993. 686:243–247.
18. Dosaka-Akita H, Shindoh M, Fujino M, Kinoshita I, Akie K, Katoh M, et al. Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patient smoking history. Am J Clin Pathol. 1994. 102:660–664.
19. Le Calvez F, Mukeria A, Hunt JD, Kelm O, Hung RJ, Taniere P, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res. 2005. 65:5076–5083.
20. Martin B, Verdebout JM, Mascaux C, Paesmans M, Rouas G, Verhest A, et al. Expression of p53 in preneoplastic and early neoplastic bronchial lesions. Oncol Rep. 2002. 9:223–229.
21. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res. 2005. 11:3974–3986.
22. D'Amico TA, Massey M, Herndon JE 2nd, Moore MB, Harpole DH Jr. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg. 1999. 117:736–743.
23. Harpole DH Jr, Herndon JE 2nd, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 1995. 55:51–56.
24. Kwiatkowski DJ, Harpole DH Jr, Godleski J, Herndon JE 2nd, Shieh DB, Richards W, et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol. 1998. 16:2468–2477.
25. Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol. 1997. 15:2858–2865.
26. Haga Y, Hiroshima K, Iyoda A, Shibuya K, Shimamura F, Iizasa T, et al. Ki-67 expression and prognosis for smokers with resected stage I non-small cell lung cancer. Ann Thorac Surg. 2003. 75:1727–1732.
27. Han H, Landreneau RJ, Santucci TS, Tung MY, Macherey RS, Shackney SE, et al. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Hum Pathol. 2002. 33:105–110.
TOOLS
Similar articles